PREMATRICS: Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery

Sponsor
Kepler University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04856618
Collaborator
(none)
3,782
1
13.1
288.5

Study Details

Study Description

Brief Summary

Cardiac surgery is one of the clinical surgical specialties that carries a particularly high risk for patients to suffer from severe bleeding perioperatively and consequent anemia, which subsequently requires transfusion of allogeneic blood.

Although a surprisingly high number of patients in cardiac surgery do not require perioperative transfusions, it is primarily those patients who do require transfusion who are subsequently at risk for a worse outcome.

In recent years many studies have been published discussing measures that can assist physicians in avoiding the triad of anemia, bleeding, and transfusion in cardiac surgery. Within these publications, the implementation of Patient Blood Management (PBM) is advised. PBM is a set of measures aimed at improving patient outcome by reducing perioperative bleeding and thus preventing both anemia and bleeding.

The three pillars of this bundle are the preoperative preparation of anemic patients with iron, erythropoietin, folic acid and vitamin B12, the prevention of intraoperative blood loss and the reasonable indication for allogeneic transfusions.

Nevertheless, it must be mentioned that the implementation of at least part of these measures is laborious, and full implementation of the recommended bundle is therefore rarely achieved. As a consequence, the full potential of Patient Blood Management is not always realized. Unfortunately this means that transfusion of allogeneic blood cannot be prevented in many patients.

A small proportion of patients undergoing cardiac surgery requires a very large amount of allogeneic blood perioperatively. These patients are typically those with a particularly poor outcome. Massive transfusion of allogeneic blood in this situation is an indicator of complications and a cause of increased mortality.

Although cardiac surgeons and anesthesiologists believe they can assess which patients are at high risk for hemorrhage, recent publications indicate that there is an urgent need for adequate predictive methods. A variety of studies exist that attempt to predict perioperative transfusion requirements, but to date have been plagued by several limitations. Either the previous publications do not focus on the prediction of massive transfusion of allogeneic blood, i.e. administration of ten or more packed red blood cell units perioperatively, but on much lower transfusion volumes, have only low predictive strength to predict massive transfusion in daily clinical practice, or are hardly usable for true prediction because they use factors (features) that are not strictly present only in the preoperative phase.

If an accurate prediction model based on a few features could be created and those patients particularly at risk of massive transfusion of allogeneic blood could be identified, it would subsequently be possible to develop an adapted clinical pathway that would allow patient care to be improved and individualized interventions adapted to the situation to be implemented.

In the best case, an adapted care of patients would be possible, which is able to increase the acceptance for the use of even complex measures of patient blood management. This is especially true for measures such as preoperative preparation with iron and/or erythropoietin, the use of a cell saver, and a particularly careful surgical approach.

Even if it is difficult to apply all measures of patient blood management in all patients, it would be possible with an approach as described to identify those patients who would benefit most from individualized approaches.

Condition or Disease Intervention/Treatment Phase
  • Biological: Massive Transfusion of Allogeneic Blood

Study Design

Study Type:
Observational
Actual Enrollment :
3782 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery
Actual Study Start Date :
Jun 16, 2021
Actual Primary Completion Date :
Jun 30, 2021
Actual Study Completion Date :
Jul 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Massive Transfusion Positive

Massive Transfusion Positive

Biological: Massive Transfusion of Allogeneic Blood
Massive Transfusion of Allogeneic Blood, > pRBCs

Massive Transfusion Negative

Massive Transfusion Negative

Outcome Measures

Primary Outcome Measures

  1. AUROC for Classification of Necessity for Massive Transfusion [2010-01-01 to 2019-12-31]

    AUROC for Classification of Necessity for Massive Transfusion

Secondary Outcome Measures

  1. Confusion Matrix Values [2010-01-01 to 2019-12-31]

    Confusion Matrix Values

  2. Descriptive Statistics [2010-01-01 to 2019-12-31]

    Descriptive Statistics (age, gender, EuroSCORE II, ASA, NYHA, CCS, main surgical procedure, ventricular ejection fraction, endocarditis present, myocardial infarction present, chronic pulmonary disease, immediacy requirement of procedure (elective, emergency), arteriopathy present, diabetes present, previous cardiac surgery done, critical condition present, aortic surgery, pulmonary hypertension present, renal impairment (none, moderate, severe, dialysis)).

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients that underwent cardiac surgery at the Kepler University Hospital in the period between 2010-01-01 and 2019-12-31.
Exclusion Criteria:
  • Patients below 18 years of age.

  • Presence of congenital heart disease.

  • Revision surgery of the same patient.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kepler University Hospital Linz Upper Austria Austria 4021

Sponsors and Collaborators

  • Kepler University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Thomas Tschoellitsch, Investigator, Kepler University Hospital
ClinicalTrials.gov Identifier:
NCT04856618
Other Study ID Numbers:
  • PREMATRICS
First Posted:
Apr 23, 2021
Last Update Posted:
Jul 22, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Thomas Tschoellitsch, Investigator, Kepler University Hospital

Study Results

No Results Posted as of Jul 22, 2022